TARGT First is a focused genomic test designed for patients who are newly diagnosed and need quick, reliable insights to guide first-line treatment decisions.

Not every patient needs a very large genomic panel at the beginning. TARGT First provides essential information without unnecessary complexity, helping doctors move forward confidently.

Many cancer tests look only at hotspot regions of genes. This means important mutations outside those regions can be missed. TARGT First:

• Analyzes 92 full-length genes
• Covers markers related to:
  
  • Targeted therapies
  • Prognosis
  • Pharmacogenomics (how your body processes drugs)

TARGT First may be suitable if:

• You are newly diagnosed
• Your cancer appears localized or less complex
• Your doctor needs fast, actionable insights to plan treatment

Choosing the right test early can mean:

• Fewer repeat tests
• Faster treatment decisions
• Better clarity on prognosis and treatment response
• Greater confidence for you and your doctor

Sometimes, smaller or limited tests do not identify the biomarkers needed to guide treatment. In such cases, your doctor may recommend a more comprehensive test.

TARGT Indiegene is a highly comprehensive genomic test that analyzes 1,212 genes, helping uncover deeper molecular insights.

Indiegene evaluates important biomarkers such as:

• TMB (Tumor Mutational Burden)
• MSI (Microsatellite Instability)
• HRD (Homologous Recombination Deficiency)
• Gene fusions and rare variants

These markers are crucial for determining eligibility for immunotherapy, PARP inhibitors, and other advanced treatments.

Cancer genetics vary across populations. Many global panels are built mainly using Western datasets, which may miss important variants in Asian and other under-represented populations.

Indiegene combines:

• Gene discoveries from South Asian tumor research
• Cancer genes validated across global literature

This makes it inclusive, accurate, and representative for diverse patients worldwide.

SoLiQ combines three genomic sources into one integrated analysis:

1. Tissue DNA (FFPE) – core tumor mutations
2. Liquid biopsy (ctDNA) – real-time tumor evolution
3. Germline DNA – inherited vs acquired mutation clarity

Most labs perform these tests separately and give three separate reports.

SoLiQ integrates all three into one intelligent report that:

• Identifies true somatic mutations
• Flags CHIP mutations
• Captures tumor heterogeneity
• Tracks resistance and disease evolution

SoLiQ may be recommended if:

• Tissue is older than 6 months or limited
• You have multiple primaries
• Cancer is metastatic or aggressive
• Disease has progressed on prior therapy
• The primary cancer site is unknown (CUP)

Whole Exome Sequencing (WES) is a genomic test that analyzes all protein-coding genes in the human genome — approximately 20,000 genes. These genes contain the instructions that control how cells grow, divide, and function.

Since most disease-causing mutations occur in these coding regions, WES provides the most comprehensive view of the genetic changes driving a cancer.

Targeted panels analyze a fixed set of selected genes (for example, 50, 100, or even 1,000 genes). They are designed to look for known, common mutations.

Whole Exome Sequencing goes much further:

• It examines every coding gene, not just a predefined list
• It can detect rare, novel, or unexpected mutations
• It captures complex pathway alterations that smaller panels may miss

In simple terms, targeted panels read selected chapters, while WES reads the entire book.

No single test is right for everyone. Whole Exome Sequencing is most often used in complex cases, and your oncologist is best placed to decide if it is appropriate for you. A simple way to think about it: If targeted panels are like looking at a short list of suspects, Whole Exome Sequencing investigates everyone involved — ensuring nothing important is overlooked.

Cancer biology is complex and varies from patient to patient. Smaller panels may miss:

• Rare mutations outside the selected gene list
• Novel variants not yet well-studied
• Unusual pathway interactions
• Secondary or resistance mutations

When no clear answer emerges from a targeted panel, WES can often reveal insights that were previously hidden.

TARGT Absolute is the most comprehensive molecular profiling test available, integrating:

• Whole Exome DNA
• Whole Exome RNA
• Whole exome Germline DNA
• 1212 genes Liquid biopsy (ctDNA)
• AI-based biosimulation intergrated (Cellworks)

While many panels analyze a few hundred genes, Absolute examines ~20,000 genes — the entire exome.

This allows detection of:

• Rare and novel mutations
• RNA expression changes
• Deep pathway disruptions
• Resistance mechanisms
• Ultra-rare actionable targets

Using Celloworks AI biosimulation, Absolute can:

• Model drug response at a cellular level
• Simulate pathway interactions
• Identify potential treatment sensitivities
• Provide deeper insight when conventional markers are inconclusive

Absolute may be considered when:

• Cancer is advanced, rare, or complex
• Multiple treatments have already been tried
• Earlier tests did not find actionable options
• Your doctor wants the most exhaustive assessment possible

There is no one-size-fits-all answer. The right test depends on:

• Your cancer type and stage
• Prior test results
• Treatment history
• Clinical complexity

Your oncologist is best placed to guide this decision — and these tests are designed to support that step-by-step approach.